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Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Low-grade systemic
inﬂammation is considered a hallmark of COPD that potentially links COPD to increased rate of systemic manifestations of the
disease. Obesity with/without the metabolic syndrome and cachexia represent two poles of metabolic abnormalities that may
relate to systemic inﬂammation. On one hand systemic inﬂammatory syndrome likely reﬂects inﬂammation in the lungs, i.e.
results from lung-to plasma spillover of inﬂammatory mediators. On the other hand, obesity-related hypoxia results in local
inﬂammatoryresponsewithinadiposetissueperse,andmaycontributetoelevationsincirculatorymediatorsbyspilloverfromthe
adipose tissue to the systemic compartment. The extent to which systemic hypoxia contributes to the adipose tissue inﬂammation
remains unknown. We assume that in patients with COPD and concurrent obesity at least three factors play a role in the systemic
inﬂammatory syndrome: the severity of pulmonary impairment, the degree of obesity-related adipose tissue hypoxia, and the
severity of systemic hypoxia due to reduced pulmonary functions. The present review summarizes the epidemiological and clinical
evidence linking COPD to obesity, the role of adipose tissue as an endocrine organ, and the role of hypoxia in adipose tissue
inﬂammation.
1.Introduction
According to the WHO, chronic obstructive pulmonary
disease (COPD) is one of the most prevalent diseases,
expected to move to the 3rd leading cause of mortality
in 2020 [1]. COPD is characterized by poorly reversible
airﬂow limitation that is usually progressive and associated
with an abnormal inﬂammatory response of the lungs
to noxious particles or gases, particularly cigarette smoke
[2]. Nevertheless, the pathological mechanisms and clin-
ical manifestations of COPD are not restricted only to
pulmonary inﬂammation and airway remodeling [3]. In
contrast, over the last decade, the recognition of COPD as a
systemic disease has developed. The best recognized systemic
manifestationsofCOPDincludesystemicinﬂammation,car-
diovascular comorbidities, cachexia and muscle dysfunction,
osteoporosis, anemia, and clinical depression and anxiety [4,
5]. Chronic comorbidities aﬀect health outcomes in patients
with COPD, including mortality. In fact, the majority of
patients with COPD die of nonrespiratory disorders such as
cardiovascular diseases or cancer [6].
Low-grade systemic inﬂammation can be deﬁned as a
two- to fourfold elevation in circulating levels of proinﬂam-
matory and anti-inﬂammatory cytokines, naturally occur-
ring cytokine antagonists, acute phase proteins, as well as
minor increases in counts of neutrophil and natural killer
cells [7]. Systemic inﬂammation is considered a hallmark
of COPD and one of the key mechanisms that may be
responsible for the increased rate of comorbidities, includ-
ing cardiovascular complications in COPD [8]. Obesity
with/without the metabolic syndrome on one hand and
cachexia on the other represent two poles of metabolic
abnormalities that may relate to systemic inﬂammation.
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of obesity concurrently with COPD, particularly in GOLD
stages 1 and 2 [9]. Obesity and cachexia are clinically
signiﬁcant and challenging in both clinical practice and
translational research of systemic manifestations of COPD
[9, 10].
Increased expression and secretion of proinﬂammatory
adipokines resulting from obesity and/or hypoxia in patients
with COPD may represent a contributing mechanism aggra-
vating the overall systemic inﬂammatory pattern in this mul-
ticomponent disease. Although the extent to which adipose
tissue production and release of inﬂammatory cytokines
contributes to the chronic systemic inﬂammatory syndrome
in COPD is not yet well deﬁned, several stimulating ideas
can be derived from experimental studies aimed to unravel
the eﬀects of hypoxia in adipocyte cell cultures, from animal
hypoxic models, and from disorders other than COPD. The
purpose of this review is to summarize recent advances
and to outline future perspectives in the search for the
evidenceofthepotentialroleofadiposetissueinthesystemic
inﬂammation in patients with COPD.
2.SearchStrategy
A search of scientiﬁc literature was performed to identify
relevant studies on the topic. Following electronic databases
were searched: Cochrane Database of Systematic Reviews,
Medline via PubMed, and Google Scholar. Speciﬁc key-
words, terms, and their combinations including searches
with MESH terminology (i.e., “obesity and COPD and
review”) were used in three areas: (1) terms related to
clinical manifestations of COPD: “chronic obstructive pul-
monary disease”, “adipose tissue”, “morbidity”, “mortality”,
“clinical outcomes”, “exacerbation”, “comorbidities”, “systemic
manifestations”, “obesity”, “cachexia”, “weight loss”; (2) terms
related to systemic inﬂammation: “systemic inﬂammation”,
“hypoxia”, “inﬂammatory cytokines”, “adipokines”, “transcrip-
tion factors”, “gene expression”, “tumor necrosis factor”, “inter-
leukin”, “hypoxia-inducible factor”, “nuclear factor-kappa B”;
(3) terms related to metabolic state: “insulin resistance”,
“nutrition”, “body composition”, “fat mass”, “fat-free mass”,
“resting energy expenditure”. The searches were limited to
papers published in English-language journals in the last 15
years. In addition, we searched relevant guidelines and latest
editions of internal and respiratory medicine textbooks.
Given the journal space limits, we restrict the present review
to the most robust, relevant, and important studies in the
reviewed topic.
3. SystemicInﬂammation in COPD
3.1. COPD—Chronic Systemic Inﬂammatory Syndrome.
Recently, Fabbri and Rabe [11] proposed an overreaching
approach to diagnosis, assessment of severity, and manage-
ment of COPD and its frequent comorbidities that aims not
to restrict the diagnostic approach to COPD alone but to
search for the signs of the more general disorder termed
“chronic systemic inﬂammatory syndrome”. The rationale
for this proposal described in details in Lancet [11]c a n
be shortly summarized as (a) systemic inﬂammation as
the most likely key common mechanism by which major
risk factors such as smoking, hyperlipidemia, obesity, and
hypertension lead to chronic diseases [12] including COPD,
(b) the presence of at least three chronic medical conditions
in almost half of all people aged 65 years or older, with
comorbid conditions accounting for more than 50% of
health-care resources in patients with COPD [13].
The epidemiological, pathogenetic, and clinical evidence
linking COPD to chronic systemic inﬂammatory syndrome
is rapidly growing. Even during stable COPD, increases in
a number of inﬂammatory proteins were described in the
systemic circulation including C-reactive protein (CRP) [7,
14–16], tumor necrosis factor-alpha (TNF-α), interleukin
(IL)-6 [17] and IL-8 [18]. Small but signiﬁcant increases
in circulating levels of both the soluble TNF receptors
55 and 75 (sTNF-R55 and sTNF-R75) [18], IL-10 [19]
and IL-18 [20] have also been reported in such patients.
Importantly, epidemiological studies suggest relationships
between circulatory inﬂammatory mediators and reductions
in pulmonary functions reﬂected by decreases in forced
expiratory volume in one second (FEV1). Such relationships
were observed between pulmonary functions and circulatory
CRP [7, 21]o rI L - 6[ 22]. Moreover, some evidence suggests
that the systemic proinﬂammatory state is likely not coun-
terbalanced by up-regulation of anti-inﬂammatory proteins.
Indeed, Dentener et al. [14] documented that levels of the
anti-inﬂammatory mediator-soluble interleukin 1 receptor
II (sIL-1RII) were similar in patients with stable COPD
compared to healthy subjects, despite markedly increased
sTNF-R55. It is important to underline that signiﬁcant
repeatability of circulatory inﬂammatory biomarkers such
as IL-6, TNF-α, and CRP over twelve-month period, with
a robust and repeatable association between IL-6 and CRP
levels was recently demonstrated [23].
COPD exacerbations are associated with further
increases in markers of both bronchial and systemic
inﬂammation over and above levels present during the
stable phase of the disease [24–26]. In addition, the rate
of decline of inﬂammatory mediators such as CRP during
exacerbationsofCOPDissigniﬁcantlydiminishedcompared
to other inﬂammatory conditions such as pneumonia, with
only 6% of COPD patients responding by CRP reductions
on the second day of hospitalization following antibiotic
administration [27].
3.2. Origin of Systemic Inﬂammation in COPD. Might
COPD-associated chronic inﬂammatory syndrome reﬂected
by increases in circulatory concentrations of inﬂammatory
proteins relate to concurrent obesity or cachexia? In COPD,
two main sources of inﬂammatory mediators may be consid-
ered: lungs and peripheral organs including adipose tissue.
Indeed, there is a long-lasting debate whether, in patients
with COPD, the local inﬂammation in the pulmonary
compartmentspillsoverintothecirculationorratherthereis
an enhanced production of inﬂammatory mediators in non-
pulmonary compartment as well. Approaching this question
is rather challenging since plasma biomarkers such as CRP,
TNF-α, interleukins, and ﬁbrinogen are clinically relevant
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and, thus, their relationship with COPD and lung functions
remains uncertain [30, 31]. Analysis of the origin of systemic
inﬂammation in COPD might require diﬀerent approach:
to study either lung-speciﬁc proteins (i.e., pneumo-proteins)
whoes plasma concentrations are largely determined by the
rate of synthesis and translocation across the lung-blood
barrier, and/or adipose-tissue speciﬁc proteins in association
with measurements of arteriovenous diﬀerences in the
concentrations of the respective inﬂammatory mediators
(Sin DD, personal communication).
3.2.1. Lung-to-Blood Translocation of Inﬂammatory Media-
tors. Recently, the concept of systemic inﬂammation as a
consequence of spillover of inﬂammatory mediators from
the lungs to the systemic compartment in COPD has been
broadly discussed [32–34]. Several lines of evidence suggests
that smoking per se and/or COPD increase permeability of
pulmonary vessels, and therefore contribute to the spill-
over of inﬂammatory mediators from the pulmonary to
the systemic compartment [35–38]. First, in airway cell line
in vitro, exposure to cigarette smoke transiently decreases
transepithelial resistance in association with increases in
macromolecular permeability [37]. Second, experimental
studies in mice suggest that lung injury induced by
bleomycin exposure leads to increased leak of surfactantpro-
tein D (SP-D), a lung speciﬁc protein from the pulmonary
to the systemic compartment [39]. Also, lung-to-blood
translocation of IL-6, a primary inﬂammatory cytokine, has
been documented following exposure to endotoxin [40].
Third line of evidence on the lung-to-blood translocation
of inﬂammatory mediators comes from human studies.
Kennedy et al. [35] identiﬁed higher alveolar-capillary mem-
brane permeability in smokers compared to nonsmokers
using the most direct measurement of the blood-gas bar-
rier permeability by radioactive-labeled hydrophilic solute
99mTc-labelled diethylenetriaminepentaacetic acid (DTPA)
following its inhalation and clearance from the alveoli into
the pulmonary capillary blood. Moreover, Wollmer and
Evander [36] demonstrated that lung clearance of DTPA is
inversely related to FEV1 such that subjects with the lowest
pulmonary function had the highest values of permeability.
Conversely, improvements in FEV1 following therapy with
inhaled steroids were accompanied by signiﬁcant reductions
inalveolar-capillarymembranepermeabilityinsymptomatic
patients with COPD [41]. Also, reductions in serum levels
of several inﬂammatory mediators including lung-speciﬁc
proteins such as surfactant protein-D were observed in
patients with moderate-tosevere COPD following therapy
with inhaled corticosteroids [42, 43].
3.2.2. Increases in Inﬂammatory Cytokine Production and
Release from Peripheral Tissues. In conditions other than
COPD, large number of studies suggest that both liver and
adipose tissue express a wide variety of proinﬂammatory
mediators that are released to the systemic circulation, and
have potential systemic eﬀects. In the pathogenesis of low-
grade subclinical inﬂammation in obesity, the importance
of adipokines released from adipose tissue is increasingly
recognized. Indeed, visceral fat is an important source of
IL -6, and portal vein IL-6 levels relate to arterial C-
reactive protein levels [44]. Nevertheless, despite observed
links between visceral adiposity and systemic inﬂammation,
no studies addressed the question regarding adipose tissue
contribution to systemic inﬂammation in patients with
COPD.
3.2.3. A Novel Concept of Systemic Inﬂammation Origin in
COPD: Dependence on Pulmonary Impairment and Obe-
sity. Three lines of evidence, that is, experimental studies,
studies in humans involving measurements of lung vascu-
lature permeability, and treatment studies in COPD with
inhaled corticosteroids support the concept that pulmonary
inﬂammation is the prevailing mechanism contributing to
systemic inﬂammation in such patients. Nevertheless, when
interpreting the above studies, one crucial factor needs to be
taken into account: the severity of lung structure/function
impairment.Sincehighestpermeabilityofpulmonaryvessels
occurs in subjects with the lowest FEV1 [36], and inhaled
corticosteroids reduced systemic inﬂammation in patients
with at least moderate degree of bronchial obstruction
[42, 43], the mechanism of inﬂammatory proteins spill-
over from the pulmonary to the systemic compartment
is likely to have the highest relevance in patients with
more pronounced pulmonary impairment. Nevertheless,
lung-to-blood translocation of inﬂammatory mediators may
not be prominent in subjects with mild form of the
disease. In contrast, the prevalence and degree of obesity
are signiﬁcantly higher in patients with mild compared to
more advanced COPD (see further) [9, 45]. Therefore, it
is reasonable to assume that obesity-related adipose tissue
inﬂammation likely represents a signiﬁcant contributor to
the overall systemic inﬂammatory proﬁle in patients with
mild form of the disease with concurrent obesity (Figure 1).
The hypothesis that adipose tissue may contribute to the
overall systemic inﬂammatory phenotype in patients with
early stages COPD with obesity or relative abundant fat mass
is novel [10]. Therefore, we discuss further essential issues
related to body composition in COPD, endocrine function
of adipose tissue, and the role of hypoxia in adipose tissue
inﬂammation.
4.Body Composition inCOPD
In patients with COPD, obesity is characterized by an abso-
lute abundance of fat mass (FM), similar to other diseases
associatedwithexcessiveadiposity(i.e.,metabolicsyndrome,
hypercorticism, etc.). The prevalence of abdominal obesity
measured by waist circumference is almost twice as high
as in age- and sex-matched controls [46]. Patients with
normal body mass index (BMI) display either physiological
or reduced ratio of fat-free mass (FFM) to FM. Importantly,
selective wasting of FFM (i.e., loss of muscle mass) occurs in
about 10% of COPD patients with normal BMI, resulting in
ar e l a t i v eo ra b s o l u t ei n c r e a s ei nF M[ 47–49]. Nevertheless,
cachectic patients with COPD experiencing reductions in
their body weight below the physiological range suﬀer from
both loss of FFM in association with the loss of FM [50].4 Mediators of Inﬂammation
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Figure 1: Concept of diﬀerential contribution of lung-to-blood translocation of inﬂammatory proteins versus adipose tissue inﬂammation
totheoverallsystemicinﬂammatoryphenotypeinCOPD.WesuggestthatinpatientswithmildCOPDandconcurrentobesity,adiposetissue
(AT) is the key contributor to systemic inﬂammation, whereas in those with severe COPD, lung-to-blood translocation of inﬂammatory
proteins plays the major role.
4.1. Epidemiology of Obesity in COPD. Obesity has emerged
as an important risk factor for respiratory disorders, and a
link between obesity and/or metabolic syndrome and COPD
is increasingly recognized [10, 51, 52]. The prevalence of
obesity is the highest among patients with milder forms
of the disease (GOLD Stages 1 and 2), and the lowest in
patients with the most severe lung function impairment in
Stage4[8,45].Marquisetal.[46]demonstratedthepresence
of one or more components of the metabolic syndrome in
almost 50% of COPD patients. Furthermore, in a recent
population-based surveythatinvolved 7,358 adultsaged ≥50
years, the risk of metabolic syndrome was higher in those
with airﬂow obstruction compared to those without [53].
In the Tucson prospective cohort study, prevalence of BMI
≥28kg/m2 was signiﬁcantly higher in patients with chronic
bronchitis compared to controls (25 versus 16%) [54].
Furthermore, two large epidemiological studies identiﬁed
increased prevalence of obesity among patients with COPD
than in the general population. In Northern California
(USA), 54% of patients with COPD were obese and had
BMI ≥30kg/m2 compared to 20–24% prevalence of obesity
in the general population [55]. In the European cohort of
COPD patients in Netherlands, obesity prevalence of 18%
was reported [9] in contrast to only 10–12% prevalence
in the general cohort of residents in the same region [55].
So far the largest and the most convincing study examined
121,965 men and women in France, and demonstrated an
independent association between lung function impairment
and the metabolic syndrome after correction for age, sex,
smoking status, BMI, physical activity, and cardiovascular
disease history [52]. Interestingly, abdominal obesity was
the strongest predictor of lung function impairment in both
men and women [52]. Similar associations between central
obesity and airﬂow obstruction that were independent of
smoking status were observed recently also in a large Chinese
cohort [53].
4.2. Putative Mechanisms. The nature of the association
between obesity and COPD has not been fully elucidated
[51]. Nevertheless, several pathogenetic mechanisms may
link these two conditions (Figure 2). First, as indicated
before, systemic inﬂammatory syndrome is a hallmark
of both conditions obesity and COPD. Second, reduced
physical inactivity is frequently observed in patients with
COPD [56]. On one hand, airﬂow limitation limits exercise
performance and reduces physical activity, and consequently
increases propensity to weight gain in patients with COPD.
On the other hand, obesity further compromises pulmonary
functions [10], and therefore represents additional factor
contributing to the patient’s inactivity (Figure 2). Impor-
t a n t l y ,ar e c e n ts t u d yb yW a t ze ta l .[ 57] demonstrated that
thecoexistingobesityandmetabolicsyndromeareassociated
with both increases in systemic inﬂammatory markers and
reduced physical activity independently of lung function
impairment. In reverse, regular physical activity modiﬁes
smoking-related lung function decline and development of
COPD [58].
4.3.ClinicalImplicationsofObesityinCOPD. Highadiposity
and fat tissue accumulation impair pulmonary functions
and exercise performance [50, 51, 55]; this topic has been
recently extensively reviewed [10]. Additionally, obesity and
the presence of metabolic syndrome are related to increased
insulin resistance in overweight and obese COPD patients
[59, 60]. The study by Bolton et al. [59] suggests that insulin
resistance is aggravated by both, high BMI and increases in
circulatory inﬂammatory mediators such as IL-6 in these
patients. Indeed, inﬂammatory mediators TNF-α,I L - 6 ,a n d
leptin were signiﬁcantly higher while plasma adiponectin
levels were reduced in the presence of excess weight in COPD
patients [51].
In patients with COPD, the relationship between body
weight and mortality risk is not unidirectional. In earlierMediators of Inﬂammation 5
Chronic obstructive pulmonary disease Obesity
Increased fat cell size
reduced blood supply
Inactivity Reduced lung function Bronchial inﬂammation
Local adipose tissue
hypoxia
Systemic hypoxia Lung-to-plasma
translocation of
inﬂammatory mediators
(“spill-over”)
Activation of
inﬂammatory pathways
in adipose tissue
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Figure 2: Proposed mechanistic links between the combined eﬀects of obesity-related local adipose tissue hypoxia, reduced lung function-
related systemic hypoxia, and bronchial inﬂammation-related increased lung-to-plasma translocation of inﬂammatory mediators on
systemic inﬂammatory proﬁle in patients with COPD.
stages of this disease, low-grade systemic inﬂammation
related to visceral obesity likely represents one of the key
factors contributing to increased risk of comorbidities such
as cardiovascular complications and type 2 diabetes. There-
fore, similar to the metabolic syndrome and type 2 diabetes,
obesity in COPD patients with GOLD Stages 1 and 2 severity
may contribute to their increased cardiovascular and all-
cause mortality [10]. In contrast, the relative mortality risk
is reduced in overweight patients with severely deteriorated
lung functions in GOLD Stages 3 and 4 [61, 62], a condition
described as “obesity paradox”. Of note, obesity paradox
has been repeatedly reported not only in severe COPD but
also in other serious conditions associated with wasting and
high mortality risk such as malignancies [63], chronic heart
failure [64], renal failure [65], and AIDS [66].
5. InﬂammatoryMediatorsandAdipose Tissue
5 . 1 .A d i p o s eT i s s u ea sa nE n d o c r i n eO r g a n .Adipose tissue
is currently viewed as a highly dynamic endocrine organ
that is involved in a wide range of metabolic processes [67–
70]. Within adipose tissue, adipocytes, macrophages, and
endothelial cells synthesize and release a large number of
a diverse group of proteins involved in several functional
categories such as inﬂammation and acute-phase response,
immunity, insulin sensitivity, angiogenesis, blood pressure
control, lipid metabolism and hemostasis [69], recommend
that the term “adipokine” be universally used to describe
proteins synthesized by and secreted from adipocytes.
Adipocytes express and secrete a variety of adipokines
including cytokines, growth factors, adiponectin, resistin,
adipsin, leptin, acylation stimulating protein, plasminogen
activator inhibitor-1 (PAI-1), lipoprotein lipase, and com-
ponents of the renin-angiotensin system which may exert
local (autocrine/paracrine) and systemic (endocrine) eﬀects
[67–69].
5.2. TNF-α and Interleukins. Marked increases in the
expression of TNF-α were identiﬁed in obese mouse models
[71], and were linked to obesity and insulin resistance.
Nevertheless, although TNF-α secretion is increased
in enlarged adipocytes, TNF-α per se has proapoptotic
properties [72]. A number of adipocyte-abundant genes
(GLUT4, hormone sensitive lipase, long-chain fatty acyl-
CoA synthase, adipocyte complement-related protein of
30kDa, and transcription factors CCAT/enhancer binding
protein-alpha, receptor retinoid X receptor-alpha, and
PPARγ) are signiﬁcantly down-regulated by TNF-α [73].
Correspondingly, exposure of adipocytes to TNF-α results in
reduced GLUT4 and several insulin signaling proteins levels
(insulin receptor, insulin receptor substrate 1, and protein
kinase (B). NF-κB is activated within 15 minutes of TNF-α6 Mediators of Inﬂammation
addition. The absence of NF-κB activation leads to a release
of more than 98% of the genes normally suppressed by TNF-
α, and, on the other hand, to a suppression of 60–70% of the
genes whose expression is physiologically induced by TNF-α
[73]. Taken together, changes in adipocyte gene expression
induced by TNF-α could lead to insulin resistance, and
NF-κB seems to be an obligatory mediator of most of these
TNF-α responses.
As much as a third of total circulating concentrations
of IL-6 has been estimated to originate from adipose tissue
[74], and circulatory concentrations of IL-6 were shown
to be related to BMI. TNF-α is a potent stimulus for
IL-6 synthesis in adipocytes: a 60-fold increase in IL-6
productionindiﬀerentiated3T3-L1adipocyteswasobserved
after TNF-α exposure [75], in association with enhanced
shedding of sTNF-RII receptors from the adipose tissue [74].
IL-6 decreases adipose tissue LPL activity, and has been
implicated in lipolysis and fat depletion taking place during
cancer cachexia [76]. Like TNF-α,I L - 6h a sp o t e n te ﬀects on
adipose tissue, as evidenced by the fact that neutralization
of this cytokine decreases progressive loss of adipose tissue
during cachexia [77].
IL-8 is also highly expressed and produced in human
adipocyte tissue, and similarly to IL-6, TNF-α represents
a potent stimulus for the production and release of IL-
8 from adipocytes. In obese subjects, positive correlations
between circulating TNF-α and IL-8 were demonstrated
[78]. Nevertheless, no data are available either on the
potential link between adipose tissue expression of IL-6 and
IL-8, and their respective circulatory levels in patients with
COPD.
5.3. Leptin and Adiponectin. Leptin, a protein synthesized by
white adipose tissue and encoded by the ob gene, plays an
important role in energy balance. Growing body of evidence
suggests that leptin may have an important role in up-
regulating the inﬂammatory system: not only does TNF-
α promote release of leptin from adipose tissue [79]b u t
leptin may per se up-regulate expression of proinﬂammatory
cytokines [80]. Plasma leptin correlates with BMI, and
weight loss reduces its circulatory concentrations in a variety
of human disorders associated with obesity [81]. Never-
theless, only a few studies analyzed associations between
lung function impairment and circulatory leptin. In 2808
nonobese individuals, Sin and Man [82] demonstrated that
those with impaired lung function have raised serum leptin
levels. In another study, Creutzberg et al. [83]d o c u m e n t e d
impairments of normal leptin feedback mechanisms during
exacerbations of COPD suggesting that elevated leptin
concentrations might represent an up-regulation of leptin
mRNA in adipose tissue resulting in an enhanced leptin
production in such patients. So far the only adipocyte-
derived hormone that is known to exert anti-inﬂammatory
eﬀects is adiponectin, and its expression is reduced in obesity
[84, 85]. Acute exacerbations of COPD are associated with
increases in serum leptin levels and the leptin/adiponectin
ratio, and these elevations were related to serum IL-6
and TNF-α [84]. In turn, adiponectin levels increased at
resolution of COPD exacerbation [86].
5.4.AdipocyteTissueHypoxiainObesity:EﬀectsonInﬂamma-
tory Mediators. The expression and/or secretion of inﬂam-
matory molecules are increased in the adipose tissue of
obese insulin-resistant individuals. In contrast to small
adipocytes,enlargedadipocytesinconditionsassociatedwith
obesity express proinﬂammatory and anti-inﬂammatory
factors with a shift towards dominance of proinﬂammatory
adipokines [87]. Elevated levels of IL-6 were detected in
obese women, and were reduced after weight loss [88]. In
addition, increased expression of inﬂammatory mediators
such as TNF-α [71, 89], PAI-1 [90], and leptin [89]w a s
detected in human obesity.
Chronic low-grade adipose tissue inﬂammation in obe-
sity may represent a speciﬁc response to relative hypoxia
of adipocytes [69] .S e v e r a lf a c t o r sm a yc o n t r i b u t et oc e l l
hypoxia within adipose tissue in association with high
adiposity: (a) blood ﬂow per unit adipose tissue mass is
reduced in obese humans [91] resulting in decreased blood
supply to the tissue; (b) large adipocytes are further from the
vasculature than the normal diﬀusion distance for O2 (150
versus 100μm). Therefore, clusters of adipocytes become
distant from the vasculature as cell size increases resulting in
their relative hypoxia and increased inﬂammatory response
which serves to increase blood ﬂow and to stimulate
angiogenesis [69].
Adipocyte tissue hypoxia has detrimental eﬀects on
cell metabolism and function, as evidenced by studies in
vitro and animal models. Studies in vitro have shown that
hypoxia results in enhanced TNF-αproduction, increased
expression of PAI-1, and reduced adiponectin and per-
oxisome proliferator-activated receptor gamma (PPARγ)
expression [92, 93]. In addition, animal models in obese
mice demonstrated occurrence of hypoxia in adipose tissue
in association with increased expression of proinﬂam-
matory adipokines [93]. Hypoxia-induced factor (HIF)-
1αrepresents the key hypoxia-sensing protein in most tis-
sues. Not only does it play a central role by signaling the
presence of hypoxia to the transcriptional systems in the
nuclei of allcellsbutit alsoactivates a number of target genes
whose products are involved in inﬂammatory responses
such as IL-6, TNF-α, macrophage migration inhibitory
factor, vascular endothelial growth factor, tissue inhibitor
of metalloproteinases-1, and monocyte chemotactic protein
[94, 95]. Transcription factors such as NF-κBa n ds t e r o l
regulatory element-binding protein (SREBP) are down-
stream molecules of HIF-1α signaling pathways that in turn
regulate production of TNF-α and IL-6 [96]. The number of
identiﬁed genes with demonstrated responsiveness to HIF-
1α is steadily growing, and to date more than 70 genes
have been described as targets of this molecule [94]. These
genes encode proteins involved in energy metabolism, cell
proliferation, apoptosis, and angiogenesis [97–99]. Genes
whose expression is up- or down-regulated in adipocytes by
hypoxia have been recently extensively reviewed elsewhere
[100].
5.5. Systemic Hypoxia in Respiratory Disorders. Signiﬁcant
inverse relationships were observed between PaO2 and circu-
lating TNF-α and staﬀ-R levels in patients with COPD [101].Mediators of Inﬂammation 7
Lipid peroxidation products are increased, and antioxidative
enzymes are reduced in the circulation of patients with
COPD at rest and during exercise [102], and increase
even further during exacerbations of the disease [103]. In
addition,anassociationbetweenmarkersofsystemicinﬂam-
mation and markers of oxidative stress during exacerbations
of COPD was described [103]. However, no studies were
undertakenuntilnowtoanalyzeadiposetissueinﬂammation
in patients either with stable COPD or during the disease
exacerbations. It is reasonable to hypothesize that increases
in proinﬂammatory cytokine expression and their release
from adipose tissue to the systemic compartment occur not
only in response to local obesity-related tissue hypoxia but
also in response to systemic hypoxia resulting from reduced
pulmonary functions. Nevertheless, it is unclear whether
systemic hypoxia exerts additional or multiplicative eﬀects
on adipose tissue in patients with COPD and concurrent
obesity.Interestingly,similaruncertaintiesdwellinthesearch
for the potential synergistic negative eﬀects of obesity and
obstructive sleep apnea, a condition characterized by repet-
itive cessation of breathing during sleep and intermittent
hypoxia [104]. While the association between sleep apnea
and systemic inﬂammation has been repeatedly reported
[105–107], and the eﬀects of intermittent hypoxia on
metabolic derangements and systemic inﬂammation have
been documented in animal models [108–111], the topic of
adipose tissue response to intermittent hypoxia in patients
with sleep apnea is still unexplored. Similarly, the study of
the eﬀects of chronic systemic hypoxia related to COPD on
adipocyte structure and function represents a major research
challenge.
5.6. Cross-Talk between Adipocyte Tissue and Lungs: Search
for Evidence. Epidemiological evidence that links COPD
to obesity and metabolic syndrome, in association with
pleiotropic character of most inﬂammatory mediators, sug-
gests that a physiologically and clinically relevant cross-
talk might exist between the lungs and adipocyte tissue.
Although such concept has not been yet directly studied in
detail, several ﬁndings suggest that this hypothesis worth
further exploration. First, receptors of two typical adipocyte-
derived cytokines, leptin, and adiponectin, are expressed
in peripheral tissues including lung [112, 113]. Interest-
ingly, increased leptin expression in bronchial mucosa was
observed in patients with COPD, in association with airway
inﬂammation and airﬂow obstruction [112, 114]. Moreover,
leptin receptor polymorphisms were linked to the decline
in pulmonary functions, and leptin receptor is considered a
novel candidate gene for COPD [115], whereas adiponectin
may attenuate allergen-induced airway inﬂammation and
hyperresponsiveness suggesting its potential protective role
within the airways [116]. In turn, expression of SP-D,
the protein that was originally thought to be restricted
to the pulmonary compartment, was recently located in
both epithelial cells of multiple mucosal surfaces and in
endothelial cells [117]. Interestingly, genetic variations in
serum SP-D and BMI are correlated [118], and a negative
association between serum SP-D and obesity measures was
observed in humans [117]. Nevertheless, the nature of the
association remains unknown and additional research is
needed in this ﬁeld.
6. Conclusion andFuturePerspectives
A new paradigm may emerge in the approach to analyze
key question whether adipose tissue contributes to systemic
inﬂammationinsuchdisordersthatareassociatedwithboth,
obesity and systemic hypoxia. Approaching this question is
relevant in at least two highly prevalent conditions in human
respirology, that is, COPD and sleep apnea. On one hand,
in patients with COPD, systemic inﬂammatory phenotype
likely reﬂects inﬂammation in the lungs, that is, results
from lung-to-plasma spillover of inﬂammatory mediators.
On the other hand, however, obesity-related hypoxia evokes
local inﬂammatory response within adipose tissue per se,
and systemic hypoxia likely contributes to the adipose
tissue inﬂammation. If so, elevated circulating levels of
inﬂammation-relatedproteinsmayreﬂectalsospilloverfrom
the adipose tissue to the systemic circulation in patients with
COPD and concurrent obesity. Taken together, although
current evidence suggests that lung inﬂammation and spill-
over of inﬂammatory mediators to the systemic compart-
ment represent key mechanisms of systemic inﬂammation
in COPD, both lung and adipose tissue origin of increased
levels of circulatory inﬂammatory proteins likely coincide in
some patients. The relative impact of the two mechanisms
may depend on at least three factors: severity of pulmonary
impairment (i.e., the rate of translocation of inﬂammatory
mediators from the lungs to the systemic circulation), the
degree of obesity-related adipose tissue hypoxia, and the
severity of systemic hypoxia due to reduced pulmonary
functions (Figure 1). Future studies are urgently needed to
address these questions.
Ultimately, the crucial task is to develop novel therapies
that would be eﬀective in reductions in systemic inﬂam-
mation, and in reductions of mortality in patients with
COPD. In this regard, anti-inﬂammatory drugs, adipokines,
hormones, and appetite stimulants are in the center of
research interest. Eﬀective anti-inﬂammatory therapies carry
thepotentialthattheywillnotonlysuppresssystemicinﬂam-
mation but also treat comorbid conditions and systemic
manifestations of the disease [3]. Future translational and
clinical research overlapping respirology and metabolism
with the aim to unravel the role of adipose tissue in COPD-
associated comorbidities is highly warranted.
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